Login
$ABBV
$294.55 After hours

$ABBV SEC Filings

Filed On Filing
12 Nov 2026 Form 4: Stewart Jeffrey Ryan, EVP, CHIEF COMMERCIAL OFFICER

Received 40,619 shares by exercise or conversion ($4.13M) · Sold 40,619 shares ($11.9M) · Gave 3,450 shares as a gift

09 Nov 2026 144
03 Nov 2026 10-Q
02 Nov 2026 8-K: Departure/Election of Directors or Officers; Compensation

On October 28, 2026, Jennifer L. Davis, a Class II director of AbbVie Inc. (“AbbVie”), notified the Company’s Board of Directors (the “Board”), of her intent to resign from the Board, effective November 2, 2026, in light of her recent ap...

30 Oct 2026 8-K: Results of Operations and Financial Condition

NORTH CHICAGO, Ill., October 30, 2026 – AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2026.

23 Oct 2026 Form 3: Carethers John, Director

No securities owned

15 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation

On October 14, 2026, AbbVie Inc. (“AbbVie”) expanded the size of its Board of Directors (the “Board”) from twelve directors to thirteen directors and appointed Dr. John M. Carethers as a Class II director. Dr. Carethers currently serves ...

05 Oct 2026 8-K: Results of Operations and Financial Condition

a The Company's 2026 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones expense that may be incurred beyond the third quarter of 2026, as both cannot be reliably forecasted.

02 Oct 2026 Form 4: Quaggin Susan E, Director

Granted 59 Stock Equivalent Units ($15.4K)

02 Oct 2026 Form 4: Rapp Edward J, Director

Granted 129 Stock Equivalent Units ($33.7K)

03 Sep 2026 8-K: Regulation FD Disclosure

Acquisition deepens AbbVie's robust immunology pipeline with diverse assets targeting dermatologic, respiratory and other inflammatory and immunological diseases

18 Aug 2026 Form 4: Donoghoe Nicholas, EVP, CHIEF BUS/STRAT OFFICER

Received 32,710 shares by exercise or conversion ($2.58M) · Sold 32,710 shares ($8.18M)

18 Aug 2026 8-K: Other Events

SUPPLEMENTAL INDENTURE NO. 13, dated as of August 18, 2026 (this “Supplemental Indenture”), by and between ABBVIE INC., a Delaware corporation (the “Company”) and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, a national banking associat...

14 Aug 2026 144
06 Aug 2026 424B5
05 Aug 2026 8-K: Other Events

AbbVie Inc., a Delaware corporation (the “Company”), proposes to issue and sell to Morgan Stanley & Co. LLC, BofA Securities, Inc., J.P. Morgan Securities LLC and SG Americas Securities, LLC (together, the “Representatives”) and the othe...

05 Aug 2026 FWP
04 Aug 2026 424B5
03 Aug 2026 10-Q
31 Jul 2026 8-K: Results of Operations and Financial Condition

NORTH CHICAGO, Ill., July 31, 2026 – AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2026.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support